[{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Avior Bio","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Nalmefene Hydrochloride","moa":"OPRM1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Hillstream BioPharma \/ Hillstream BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Hillstream BioPharma \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Applied Biomedical Science Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hillstream BioPharma \/ Hillstream BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Hillstream BioPharma \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Applied Biomedical Science Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hillstream BioPharma \/ Hillstream BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Hillstream BioPharma \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Sapien Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Salinomycin","moa":"||antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Sapien Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Sapien Biosciences"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Public Offering","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Thinkequity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Thinkequity"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"OncoBay Clinical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Hillstream BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Thinkequity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Thinkequity"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Thinkequity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Thinkequity"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSB-510","moa":"HDAC-6\/PI3K delta","graph1":"Oncology","graph2":"Preclinical","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HSB-510","moa":"HDAC-6\/PI3K delta","graph1":"Oncology","graph2":"Preclinical","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Minotaur Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"HSB-1940","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Minotaur Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hillstream BioPharma \/ Minotaur Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Hillstream BioPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Through the agreement, Hillstream aims to acquire a clinical stage asset, AV104 (nalmefene), an opioid antagonist, but first it intends to seek approval in an orphan disease for the treatment of moderate to severe cholestatic pruritis with primary biliar...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 09, 2023

                          Lead Product(s) : Nalmefene Hydrochloride

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Avior Bio

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : HSB-1216, is a novel and potent inducer of a powerful mechanism involving iron-mediated cell death. It is an emerging new anti-cancer mechanism, resulting in iron mediated cell death (IMCD) of drug resistant cancers.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          October 04, 2023

                          Lead Product(s) : Salinomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : HSB-510 is a novel highly targeted bifunctional inhibitor encapsulated in quatramer with single digit nanomolar IC 50 against PI3-Kδ and HDAC6, which is also known to downregulate MYC, a highly pursued and yet undruggable cancer target.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 02, 2023

                          Lead Product(s) : HSB-510

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The agreement aims to develop proprietary multi-format biologics, including bi-specific antibodies, and antibody drug conjugates (ADCs) by leveraging ABSI's technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 07, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Applied Biomedical Science Institute

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The Company intends to use the net proceeds from the offering for the advancement of HSB-1216, a novel and potent inducer of a powerful mechanism involving iron-mediated cell death, and the development of other product candidates in the Company’s pipel...

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          April 27, 2023

                          Lead Product(s) : Salinomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Thinkequity

                          Deal Size : $2.6 million

                          Deal Type : Public Offering

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the agreement, OncoBay will provide comprehensive clinical and regulatory support for the clinical development program for Hillstream's lead drug HSB-1216, which targets ferroptosis, an emerging new anti-cancer mechanism, resulting in IMCD of drug ...

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          April 13, 2023

                          Lead Product(s) : Salinomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : OncoBay Clinical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Hillstream has the option to license technology for HER2 and HER3 Conformational Domain Bridging Epitopes in antibodies to develop proprietary multi-format biologics against drug resistant cancers including HER2-positive metastatic breast, gastric, lung ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 13, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Applied Biomedical Science Institute

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The Company intends to use the net proceeds for the advancement of its lead drug candidate HSB-1216, which targets ferroptosis, an emerging new anti-cancer mechanism, and the development of other product candidates in the Company’s pipeline.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          February 05, 2023

                          Lead Product(s) : Salinomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Thinkequity

                          Deal Size : $2.6 million

                          Deal Type : Public Offering

                          blank

                          09

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc., to develop anti-MUC1-C antibodies to selectively deliver Hillstream’s Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          January 31, 2023

                          Lead Product(s) : Salinomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Dana-Farber Cancer Institute

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The net proceeds from the initial public offering will be used to advance the Company’s product candidate HSB-1216 through pre-clinical activities, completion of Phase 1 studies and manufacturing, to advance the Company’s candidate HSB-888 through pr...

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          November 01, 2022

                          Lead Product(s) : Salinomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Thinkequity

                          Deal Size : $15.0 million

                          Deal Type : Public Offering

                          blank